PT - JOURNAL ARTICLE AU - Klaric, Lucija AU - Gisby, Jack S. AU - Papadaki, Artemis AU - Muckian, Marisa D. AU - Macdonald-Dunlop, Erin AU - Zhao, Jing Hua AU - Tokolyi, Alex AU - Persyn, Elodie AU - Pairo-Castineira, Erola AU - Morris, Andrew P AU - Kalnapenkis, Anette AU - Richmond, Anne AU - Landini, Arianna AU - Hedman, Åsa K. AU - Prins, Bram AU - Zanetti, Daniela AU - Wheeler, Eleanor AU - Kooperberg, Charles AU - Yao, Chen AU - Petrie, John R. AU - Fu, Jingyuan AU - Folkersen, Lasse AU - Walker, Mark AU - Magnusson, Martin AU - Eriksson, Niclas AU - Mattsson-Carlgren, Niklas AU - Timmers, Paul R.H.J. AU - Hwang, Shih-Jen AU - Enroth, Stefan AU - Gustafsson, Stefan AU - Vosa, Urmo AU - Chen, Yan AU - Siegbahn, Agneta AU - Reiner, Alexander AU - Johansson, Åsa AU - Thorand, Barbara AU - Gigante, Bruna AU - Hayward, Caroline AU - Herder, Christian AU - Gieger, Christian AU - Langenberg, Claudia AU - Levy, Daniel AU - Zhernakova, Daria V. AU - Smith, J. Gustav AU - Campbell, Harry AU - Sundstrom, Johan AU - Danesh, John AU - Michaëlsson, Karl AU - Suhre, Karsten AU - Lind, Lars AU - Wallentin, Lars AU - Padyukov, Leonid AU - Landén, Mikael AU - Wareham, Nicholas J. AU - Göteson, Andreas AU - Hansson, Oskar AU - Eriksson, Per AU - Strawbridge, Rona J. AU - Assimes, Themistocles L. AU - Esko, Tonu AU - Gyllensten, Ulf AU - Baillie, J. Kenneth AU - Paul, Dirk S. AU - Joshi, Peter K. AU - Butterworth, Adam S. AU - Mälarstig, Anders AU - Pirastu, Nicola AU - Wilson, James F. AU - Peters, James E. TI - Mendelian randomisation identifies alternative splicing of the FAS death receptor as a mediator of severe COVID-19 AID - 10.1101/2021.04.01.21254789 DP - 2021 Jan 01 TA - medRxiv PG - 2021.04.01.21254789 4099 - http://medrxiv.org/content/early/2021/04/07/2021.04.01.21254789.short 4100 - http://medrxiv.org/content/early/2021/04/07/2021.04.01.21254789.full AB - Severe COVID-19 is characterised by immunopathology and epithelial injury. Proteomic studies have identified circulating proteins that are biomarkers of severe COVID-19, but cannot distinguish correlation from causation. To address this, we performed Mendelian randomisation (MR) to identify proteins that mediate severe COVID-19. Using protein quantitative trait loci (pQTL) data from the SCALLOP consortium, involving meta-analysis of up to 26,494 individuals, and COVID-19 genome-wide association data from the Host Genetics Initiative, we performed MR for 157 COVID-19 severity protein biomarkers. We identified significant MR results for five proteins: FAS, TNFRSF10A, CCL2, EPHB4 and LGALS9. Further evaluation of these candidates using sensitivity analyses and colocalization testing provided strong evidence to implicate the apoptosis-associated cytokine receptor FAS as a causal mediator of severe COVID-19. This effect was specific to severe disease. Using RNA-seq data from 4,778 individuals, we demonstrate that the pQTL at the FAS locus results from genetically influenced alternate splicing causing skipping of exon 6. We show that the risk allele for very severe COVID-19 increases the proportion of transcripts lacking exon 6, and thereby increases soluble FAS. Soluble FAS acts as a decoy receptor for FAS-ligand, inhibiting apoptosis induced through membrane-bound FAS. In summary, we demonstrate a novel genetic mechanism that contributes to risk of severe of COVID-19, highlighting a pathway that may be a promising therapeutic target.Competing Interest StatementDr Petrie reports personal fees from Merck KGaA, non-financial support from Merck KGaA, personal fees from Novo Nordisk, personal fees from IQVIA, grants from Janssen, personal fees from Biocon, non-financial support from Astra Zeneca, personal fees from ACI Clinical, all outside the submitted work. Ownership in companies providing services to Itrim, Amgen, Janssen, Novo Nordisk, Eli Lilly, Boehringer, Bayer, Pfizer and AstraZeneca, outside the submitted work John Danesh reports grants, personal fees and non-financial support from Merck Sharp & Dohme (MSD), grants, personal fees and non-financial support from Novartis, grants from Pfizer and grants from AstraZeneca outside the submitted work. John Danesh sits on the International Cardiovascular and Metabolic Advisory Board for Novartis (since 2010); the Steering Committee of UK Biobank (since 2011); the MRC International Advisory Group (ING) member, London (since 2013); the MRC High Throughput Science 'Omics Panel Member, London (since 2013); the Scientific Advisory Committee for Sanofi (since 2013); the International Cardiovascular and Metabolism Research and Development Portfolio Committee for Novartis; and the Astra Zeneca Genomics Advisory Board (2018). OH has acquired research support (for the institution) from AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, GE Healthcare, Pfizer, and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Alzpath, Biogen, Cerveau and Roche. PKJ is a consultant to Humanity, Inc., a company developing direct-to-consumer measures of biological aging and an advisor to Global Gene Corp, a company developing direct-to-consumer and business-to-business genomic solutions. Adam Butterworth reports grants outside of this work from AstraZeneca, Biogen, BioMarin, Bioverativ, Merck, Novartis, Pfizer and Sanofi and personal fees from Novartis. Dr Peters has received travel and accommodation expenses and hospitality from Olink to speak at Olink-sponsored academic meetingsFunding StatementJ.F.W. and C.H, acknowledge support from the MRC Human Genetics Unit programme grant 'Quantitative traits in health and disease' (U.MC_UU_00007/10). J.E.P. acknowledges a UKRI Innovation Fellowship at Health Data Research UK (MR/S004068/2), a UKRI-DHSC COVID-19 Rapid Response Rolling Call (MR/V027638/1) and Community Jameel and the Imperial President's Excellence Fund. The work of L.K. was supported by an RCUK Innovation Fellowship from the National Productivity Investment Fund (MR/R026408/1). J.H.Z. is funded by the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). A.L. is funded by the European Union's Horizon 2020 research and innovation program IMforFUTURE, under H2020-MSCA-ITN grant agreement number 721815. B.P. is funded by a BHF Programme Grant (RG/18/13/33946). D.Z. was supported by the AHA Postdoctoral Fellowship (19POST34370115). C.K. was supperted by NHLBI contracts 75N92021D00001, 75N92021D00002, 75N92021D00003, 75N92021D00004, 75N92021D00005. J.F. was supported by the Dutch Heart Foundation IN-CONTROL (CVON2018-27), the ERC Consolidator grant (101001678) and the Netherlands Organ-on-Chip Initiative, an NWO Gravitation project (024.003.001) funded by the Ministry of Education, Culture and Science of the government of The Netherlands. N.M.C is a Wallenberg Center for Molecular Medicine Fellow. A.R. is funded by R01 HL136574 and S10OD02868. C.He. acknowledges the German Diabetes Center, (DDZ) which is funded by the German Federal Ministry of Health (Berlin, Germany), the Ministry of Culture and Science of the state North Rhine-Westphalia (Dusseldorf, Germany), and grants from the German Federal Ministry of Education and Research (Berlin, Germany) to the German Center for Diabetes Research e.V. (DZD). D.V.Z was supported by a VENI grant from NWO (194.006). J.G.S. was supported by grants from the Swedish Heart-Lung Foundation (2016-0134, 2016-0315 and 2019-0526), the Swedish Research Council (2017-02554), the European Research Council (ERC-STG-2015-679242), the Crafoord Foundation, Skane University Hospital, the Scania county, governmental funding of clinical research within the Swedish National Health Service, a generous donation from the Knut and Alice Wallenberg foundation to the Wallenberg Center for Molecular Medicine in Lund, and funding from the Swedish Research Council (Linnaeus grant Dnr 349-2006-237, Strategic Research Area Exodiab Dnr 2009-1039) and Swedish Foundation for Strategic Research (Dnr IRC15-0067) to the Lund University Diabetes Center. J.D. holds a British Heart Foundation Professorship and a NIHR Senior Investigator Award. K.M. is supported by grants from the Swedish Research Council (grant no 2002-6147, 2005-6662, 2005-8214, 2008-2202, 2011-02427, 2015-03257, 2017-00644, 2017-06100 and 2019-01291, grants from the Swedish Research Council for Health, Working Life and Welfare (https://forte.se/en/; grant numbers 2011-0346, and 2017-00721), and annual grants from Avtal om Lakarutbildning och Forskning (ALF; Agreement concerning Cooperation on Medical Education and Research) between Uppsala University and Uppsala County Council. He acknowledges the national research infrastructure SIMPLER for provisioning of facilities and experimental support. SIMPLER receives funding through the Swedish Research Council under the grant no 2017-00644. A.T. was supported by the Wellcome Trust. K.S. was supported by the Biomedical Research Program at Weill Cornell Medicine in Qatar, a program funded by the Qatar Foundation, and by multiple grants from the Qatar National Research Fund (QNRF). C.L., E.W., and N.J.W. are funded by the Medical Research Council (MC_UU_12015/1). NJW is a NIHR Senior Investigator. R.J.S. is supported by a UKRI Innovation HDR-UK Fellowship (MR/S003061/1). T.L.A was supported by NIDDK/NIH grant 1R01DK114183. J.K.B. acknowledges funding support from a BBSRC Institute Strategic Programme Grant (BBS/E/D/20002172), UKRI (MC_PC_20004, MC_PC_19025, MC_PC_1905, MRNO2995X/1) and the UK Intensive Care Society. RNA-sequencing in the INTERVAL study was supported by the Wellcome Trust (grant reference 206194/Z/17/Z), NHSBT and AstraZeneca. We thank the Sequencing Operations Team and Human Genetics Informatics Team (Guillaume Noell and Vivek Iyer) at the Wellcome Sanger Institute for performing the RNA library preparation and RNA-sequencing and analysis. EP is supported by the EU/EFPIA Innovative Medicines Initiative Joint Undertaking BigData Heart grant 116074.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The individual-level data in this study is from the INTERVAL and ORCADES studies. Ethical approval for the INTERVAL study: the UK National Research Ethics Service approved the study (reference 11/EE/0538). Ethical approval for the ORCADES study" the Research Ethics Committees in Orkney, Aberdeen (North of Scotland REC), and South East Scotland REC, NHS Lothian approved the study(reference: 12/SS/0151). The remainder of the study involved meta-analysis of pQTL summary statistics from existing approved studies and/or publically available published data. The details of the IRBs/ethics committees and approvals for these individual studies are as follows. 1) COSM cohort. Ethical approval: the Regional Ethical Review Board in Stockholm, Sweden, approved this study. 2) The Swedish Mammography Cohort. Ethical approval was given by the regional research ethics board at Karolinska Insitutet, Sweden. 3) EPIHEALTH. Ethical approval: the Ethics Committee of Uppsala University (Log. No. 2010/402) and the Swedish Data Inspection Board (No. 307-2011) approved this study. 4) ARISTOTLE: Ethical approval: Approval by the appropriate ethics committees was obtained at all sites as described in Granger et al N Engl J Med 2011; 365:981-992. DOI: 10.1056/NEJMoa1107039. 5) STABILITY. Ethical approval: at each recruiting site, the study was approved by national regulatory authorities and by local ethics committees or institutional review boards, according to local regulations, as described in N Engl J Med 2014; 370:1702-1711. DOI: 10.1056/NEJMoa1315878. 6) BIOFINDER. Ethical approval: The Regional Ethics Committee in Lund, Sweden, approved the study design. 7) VIS. Ethical approval: the ethics committee of the Sisters of Mercy University Hospital in Zagreb, Croatia, approved the study. 8) The NSPHS study. Ethical approval: the study was approved by the local ethics committee at the Uppsala University (Regionala Etikprovningsnamnden, Uppsala Dnr 2005:325). 9) ULSAM. Ethical approval: The Ethics Committee of the Faculty of Medicine at Uppsala University, Sweden, approved the studyAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data described in the manuscript is included in the Tables and Supplementary files.